EP1150656A1 - Sel de bain - Google Patents
Sel de bainInfo
- Publication number
- EP1150656A1 EP1150656A1 EP00905152A EP00905152A EP1150656A1 EP 1150656 A1 EP1150656 A1 EP 1150656A1 EP 00905152 A EP00905152 A EP 00905152A EP 00905152 A EP00905152 A EP 00905152A EP 1150656 A1 EP1150656 A1 EP 1150656A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- bath
- disodium octaborate
- bath salt
- octaborate tetrahydrate
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000019341 magnesium sulphate Nutrition 0.000 title claims abstract description 40
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 title claims abstract description 32
- RDMZIKMKSGCBKK-UHFFFAOYSA-N disodium;(9,11-dioxido-5-oxoboranyloxy-2,4,6,8,10,12,13-heptaoxa-1,3,5,7,9,11-hexaborabicyclo[5.5.1]tridecan-3-yl)oxy-oxoborane;tetrahydrate Chemical compound O.O.O.O.[Na+].[Na+].O1B(OB=O)OB(OB=O)OB2OB([O-])OB([O-])OB1O2 RDMZIKMKSGCBKK-UHFFFAOYSA-N 0.000 claims abstract description 47
- 238000003287 bathing Methods 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000004615 ingredient Substances 0.000 claims abstract description 7
- 230000029663 wound healing Effects 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 241000894006 Bacteria Species 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 241000282414 Homo sapiens Species 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 241000233866 Fungi Species 0.000 claims description 5
- 239000012676 herbal extract Substances 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- CLZJMLYRPZBOPU-UHFFFAOYSA-N disodium;boric acid;hydrogen borate Chemical compound [Na+].[Na+].OB(O)O.OB(O)O.OB(O)O.OB(O)O.OB(O)O.OB(O)O.OB(O)O.OB([O-])[O-] CLZJMLYRPZBOPU-UHFFFAOYSA-N 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 238000010348 incorporation Methods 0.000 abstract description 4
- 244000005700 microbiome Species 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000000845 anti-microbial effect Effects 0.000 abstract description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 229910021538 borax Inorganic materials 0.000 description 11
- 235000010339 sodium tetraborate Nutrition 0.000 description 11
- 239000004328 sodium tetraborate Substances 0.000 description 11
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 10
- 239000004327 boric acid Substances 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 231100000419 toxicity Toxicity 0.000 description 10
- 230000001988 toxicity Effects 0.000 description 10
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 230000003385 bacteriostatic effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical group OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 5
- 231100000167 toxic agent Toxicity 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 208000028454 lice infestation Diseases 0.000 description 4
- 241000607620 Aliivibrio fischeri Species 0.000 description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 3
- 206010061217 Infestation Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004098 cellular respiration Effects 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 239000008233 hard water Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000007163 Dermatomycoses Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- ZEFNOZRLAWVAQF-UHFFFAOYSA-N Dinitolmide Chemical compound CC1=C(C(N)=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O ZEFNOZRLAWVAQF-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000517324 Pediculidae Species 0.000 description 1
- 241000517307 Pediculus humanus Species 0.000 description 1
- 201000000376 Pediculus humanus capitis infestation Diseases 0.000 description 1
- 241000101040 Pityriasis Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000233667 Saprolegnia Species 0.000 description 1
- 241000509416 Sarcoptes Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- JLYXXMFPNIAWKQ-GNIYUCBRSA-N gamma-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-GNIYUCBRSA-N 0.000 description 1
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N gamma-hexachlorocyclohexane Natural products ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960002809 lindane Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003864 metabolising cell Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000010292 orthophenyl phenol Nutrition 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 241000556533 uncultured marine bacterium Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- This invention relates to the use of disodium octaborate tetrahydrate (D.O.T.) as the sole ingredient, or as an active component of a bath salt primarily intended for use in a bath for one or a small number of individuals .
- D.O.T. disodium octaborate tetrahydrate
- Borates are oxides of the element Boron.
- the borate to be used in the invention is refined from a naturally occurring ore found in the hot, dry climate of the Mojave Desert of Southern California.
- the natural origin of the material combined with its comprehensively defined toxicological characteristics gives a material which is safe in the intended use and which exhibits properties required of a functional bath salt.
- boric acid and borax are well documented prior art.
- the bacteriostatic and fungicidal properties of borates general benefit in wound healing.
- Boracic or boric lint has been in continuous use from 1875 to the present day.
- Borax and boric acid are used in cosmetics such as creams and with other ingredients such as powders .
- the present invention provides the use of disodium octaborate tetrahydrate as, either totally, or substantially, or in part, a bath salt, with such a bath salt exhibiting many advantages over existing bath salts and other forms of borate.
- the invention thus provides a bath salt consisting of, or comprising disodium octaborate tetrahydrate as an active ingredient thereof.
- the bath salt of the present invention may further comprise any of the group comprising surfactants, oils and herbal extracts. These are believed to extend the bacteriostatic qualities of borates. Such formulations are been designed to create a pleasant smell, to enhance other qualities such as cleansing or to suit particular skin types. For example dry skin in particular is known to benefit from the emollient properties of some oils.
- Bathing generally consists of an individual being immersed in preferably hot water for a reasonable period of time. Although this water is at a temperature that makes it comfortable to bathe in, it has the disadvantage of providing a suitable environment for the multiplication of many forms of bacteria and other microorganisms and fungi of medical importance. The occurrence and propagation of such microorganisms in said bathing medium constitutes a health risk. In such instances, the present invention has particular advantages for the bather by means of reducing the propagation of such microorganisms in the bathing medium. This is due to the bacteriostatic properties of disodium octaborate tetrahydrate. In bath salt formulations where additional ingredients are added to the DOT, these may also exhibit bacteriostatic properties, though these ingredients would not necessarily be selected for such properties.
- the present invention provides the use of DOT to prevent the build-up of bacteria and fungi in bathing environments.
- the invention also provides the use of disodium octaborate tetrahydrate to provide water softening characteristics and or wound healing characteristics m a bath salt.
- a bath salt comprising or consisting of disodium octaborate tetrahydrate.
- this bath salt preparation would be dissolved into the bathing water prior to the commencement of bathing.
- the bath salts are used m circumstances where the bathing will be done m water of a hot or warm temperature (typically between 5 and 40°C) .
- disodium octaborate tetrahydrate preparation is formulated in combination with other adjuvants and surfactants.
- the bath salt preparation has suitable characteristics. It will dissolve into a solution with the bathing medium. Essentially, the bath salt shall exert no harmful effect on either the bather or the bath.
- the bath salt preparation containing disodium octaborate tetrahydrate is incorporated into the bather's medium for beneficial effects.
- Figure 1 illustrates the IC 50 values of three tested compounds in standard aqueous buffer solution (lOmM phosphate, pH 7.2) at 25°C.
- Figure 2 illustrates a comparison of toxicities of the three compounds calculated on a weight basis.
- the Microtox assay utilises ViJbrio fischeri , a Gram-negative, luminescent marine bacterium, which belongs to the same family of organisms as Escherichia coli ( E. coli ) .
- the principle of assay is that bioluminescent light output, from the bacterium requires cellular respiration and accordingly the expenditure of metabolic activity.
- bioluminescent light output from the bacterium requires cellular respiration and accordingly the expenditure of metabolic activity.
- metabolising cells give high levels of bioluminescent light output, while dead or otherwise metabolically inactive cells limit no light.
- the light output from a culture in aqueous suspension, as measured using a luminometer is a direct measure of the health of that culture.
- the toxicity of a compound can be measured by this assay thus determining the toxic characteristics of the component and whether it will effect the cellular respiration of the bacteria which in turn will lead to a decline in the overall bio-luminescence emitted from the culture.
- the rate of decay of light output from a bacterial culture following the addition of a putative toxic compound ('toxicant') can be straightforwardly translated into an IC 50 valve the IC 50 concentration of a toxicant required to reduce the bioluminescent light output of a v. fischeri culture by fifty percent.
- An LC 50 valve is determined in a 1 hour test; while for an IC 50 valve, the concentration required to reduce the numbers of bacteria by 50%, is determined in a 30 minute test.
- HBP 2- hydroxybiphenyl
- bath salts can be formulated which deliver borates to a final concentration in the range 100 - 1000 mg/1 (0.1 - lg/1) .
- concentration given in the results at which toxicity against the bacteria is shown is perfectly workable. A lower concentration may have no, or a reduced effect.
- Table 1 Solubility of DOT and borax at varying temperatures .
- the alkalinity is an important characteristic of a bath salt .
- a remarkable attribute of borates in general and disodium octaborate tetrahydrate in particular is the fairly constant pH for a wide range of concentrations at a given temperature.
- Aqueous solutions of disodium octaborate tetrahydrate range from mildly alkaline at low concentrations to practically neutral as the concentration increases at ordinary temperatures. This property is particularly relevant to the intended application as a bath salt.
- Table 2 exemplifies the above points by comparing the percentage of disodium octaborate tetrahydrate by weight of solution to its respective pH at 23°C.
- Table 2 Comparison of the percentage of disodium octaborate tetrahydrate (DOT) by weight of solution to its respective pH at 23°C.
- DOT disodium octaborate tetrahydrate
- DOT may be formulated with many adjuvants, surfactants etc. It is envisaged that it would be preferable for all formulations to be placed in the bath, in the vicinity of the hot tap where they would be dissolved into the bathing water by means of the turbulent flow created by the hot water entering the bathing vessel, until a saturated solution is achieved.
- this bath salt preparation would be dissolved into the bathing water prior to the commencement of bathing.
- the invention is inclusive of all forms of disodium octaborate tetrahydrate which can be presented as a fine powder or as large granules or alternatively in liquid form in solution.
- the invention would be placed under the hot water tap in sufficient quantity to approach saturation for any chosen temperature. Some individuals may prefer to use a lower quantity of said DOT than others.
- disodium octaborate tetrahydrate in granular form, incorporating all herbal extracts and surfactants could be supplied in a one-use, one-bath sized "Tea Bag” style bag device .
- the bag could be suspended by means of string in the hot water stream entering the bath from the tap or placed directly in the bath.
- the bag may be made of linen or similar fabric or of man made fibres of slightly course texture, which could be used to rub and gently cleanse the skin. This would have the effect of removing dead skin cells, thus helping to remove bacteria and generally exfoliating and invigorating the skin.
- the cloth could also be used to clean the surface of the bath after use, before being disposed of.
- Borates have proven bacteriostatic properties and can help to control those bacteria responsible for skin conditions including Staphylococci and Streptococci.
- herbal extracts and surfactants are selected to enhance bacteriostatic properties.
- Protozoa In areas where inadequate treatment of the water supply is common, it has been reported that Protozoal diarrhoea can be contracted from showering and bathing. Examples are known in St Louis in the former Soviet Union. Residents in or visitors to such areas of risk could gain protection by the use of the invention.
- - Fungicidal For some forms of fungi borates are the most effective form of control available. Disodium octaborate tetrahydrate has been shown to be effective where boric acid has no effect, due to its greatly increased solubility in aqueous solution.
- Fungi that the invention will help to control include Candida albi cans , a normal comensural of the human gut, which can colonise pre-existing dermatitis, all dermatophyte infections (forms of tinea such as dandruff and athletes foot) and the yeast causative organisms of Pityriasis versicor.
- An application to which the present invention may be of particular relevance is to women who have just given birth. Following childbirth, there is a need for the mother to have a sterile bath. This is especially required when surgery or damage has occurred as part of the childbirth process. In such instances, the present invention would be of particular benefit due to the provision of sterile conditions and the promotion of wound healing and regeneration of skin cells which is facilitated by the borate esters.
- bathing in bath salts of disodium octaborate tetrahydrate is not universally acceptable.
- human infants can readily absorb many chemicals.
- infants should not bathe in bath salts.
- elderly This also applies to people with serious or extensive skin conditions.
- individuals if concerned should seek the advice of a dermatologist, or similar medical advice.
- This invention is not intended for use in public facilities where there is a risk of transmission of serious disease from one person to another. Where these risks have been overcome by use of an effective non-chemical treatment system (possibly ultra violet) then it may be safe to use the invention.
- an effective non-chemical treatment system possibly ultra violet
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
Abstract
L'invention concerne l'utilisation d'octaborate disodique tétrahydraté (ODT) en tant que composant unique ou en tant qu'un des composants d'un sel de bain destiné en premier lieu à un bain accueillant une personne ou un petit nombre de personnes. L'inclusion d'ODT dans la préparation de sel de bain permet de bénéficier de ses propriétés ci-décrites telles que l'effet antimicrobien qui réduit la propagation des micro-organismes dans le milieu du bain et aide à guérir les blessures. On peut voir que l'inclusion de cette préparation dans le milieu où se trouve le baigneur a plusieurs effets bénéfiques.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9903173.4A GB9903173D0 (en) | 1999-02-13 | 1999-02-13 | Bath salt |
| GB9903173 | 1999-02-13 | ||
| PCT/GB2000/000434 WO2000047178A1 (fr) | 1999-02-13 | 2000-02-11 | Sel de bain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1150656A1 true EP1150656A1 (fr) | 2001-11-07 |
Family
ID=10847614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP00905152A Withdrawn EP1150656A1 (fr) | 1999-02-13 | 2000-02-11 | Sel de bain |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1150656A1 (fr) |
| AU (1) | AU2678500A (fr) |
| GB (1) | GB9903173D0 (fr) |
| WO (1) | WO2000047178A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1206269A4 (fr) * | 1999-06-30 | 2007-09-12 | Don H Girvan | Compositions et procedes de traitement des troubles cutanes |
| DE10035381A1 (de) * | 2000-07-20 | 2002-02-07 | Paul Haslauer | Hautpflegevorrichtung |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672362A (en) * | 1996-09-23 | 1997-09-30 | Burnett; James | Dust mite control method using dot |
-
1999
- 1999-02-13 GB GBGB9903173.4A patent/GB9903173D0/en not_active Ceased
-
2000
- 2000-02-11 AU AU26785/00A patent/AU2678500A/en not_active Abandoned
- 2000-02-11 EP EP00905152A patent/EP1150656A1/fr not_active Withdrawn
- 2000-02-11 WO PCT/GB2000/000434 patent/WO2000047178A1/fr not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| See references of WO0047178A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9903173D0 (en) | 1999-04-07 |
| AU2678500A (en) | 2000-08-29 |
| WO2000047178A1 (fr) | 2000-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004521145A (ja) | 体臭の原因となる細菌に対する1,2−デカンジオールの使用 | |
| JPWO2009069619A1 (ja) | オゾン化界面活性剤を含有する新規組成物 | |
| CN106421217B (zh) | 一种苯扎氯铵的溶液及其制备方法 | |
| CN101537004A (zh) | 一种用于人体外阴和阴道的洁阴消毒护理液 | |
| JP3529059B2 (ja) | 抗菌消臭剤 | |
| JP4899434B2 (ja) | 新規な物理化学融合型殺菌消毒液 | |
| CN107753310A (zh) | 一种新型安全温和无刺激女性私处抑菌清洁护理三合一洗液及其制备方法 | |
| BR112021007347A2 (pt) | Composições de bioflavonoides e seu uso para purificação de água e preservação de alimentos | |
| JP7003186B2 (ja) | メゾ-2,3-ブタンジオールを含有する組成物 | |
| CN102379898A (zh) | 纳米复合皮肤消毒乳液及其制备方法 | |
| CN104815096A (zh) | 一种纳米复合皮肤消毒乳液及其制备方法 | |
| CN108014032A (zh) | 一种护臀湿巾及其制备方法 | |
| CN109069383A (zh) | 与微生物生物膜相关的皮肤病状和疾病的治疗 | |
| KR102699189B1 (ko) | 항균 및 보존제 조성물 | |
| CN109512741A (zh) | 一种精油净手凝露及其制备方法 | |
| EP1150656A1 (fr) | Sel de bain | |
| Sukamdi et al. | Formula Optimization of Antimicrobial Hand Sanitizer With Lemongrass Essential Oil | |
| CN108125797A (zh) | 一种手口湿巾及其制备方法 | |
| JP3224719B2 (ja) | ヒノキ属またはアスナロ属の常緑灌木より抽出した非刺激性でかつ金属腐食性を持たない芳香性中性樹脂油を主成分とする創傷治癒剤ならびに上皮形成促進剤 | |
| CN101548683B (zh) | 一种液体消毒剂及其制备方法 | |
| RU2158143C1 (ru) | Антисептическая жидкость "велталекс-м" | |
| CN116473075A (zh) | 一种纳米高分子聚合液晶膜安全无刺激长效消毒剂及其制备方法 | |
| KR960015185B1 (ko) | 항균성 식물추출물을 함유한 일회용 물티슈 제품 | |
| CN113521042A (zh) | 一种儿童专用无醇免洗病毒灭活消毒剂及其制备方法 | |
| JP3626071B2 (ja) | ヒノキ属またはアスナロ属の常緑灌木より抽出した非刺激性でかつ金属腐食性を持たない芳香性中性樹脂油を主成分とする育毛剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20010906 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Withdrawal date: 20020205 |